Sun Pharmaceutical Industries announced that the US FDA has accepted a New Drug Application (NDA), filed by its wholly owned subsidiary, for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%, a novel nanomicellar formulation of cyclosporine A 0.09% in a clear, preservative-free aqueous solution. OTX-101 is now under review for approval by the US FDA, marking an important developmental milestone for Sun Pharma's dry eye candidate.
Post the US FDA approval, OTX-101 will be commercialized in the US by Sun Ophthalmics, the branded ophthalmics division of Sun Pharma's wholly owned subsidiary, based in Princeton, New Jersey. Sun Ophthalmics, founded in 2015, currently markets BromSite® (bromfenac ophthalmic solution) 0.075% to eye care practitioners across US.
Since 1986, Capital Market Publishers India Pvt Ltd is undertaking equity research, publishing an investment fortnightly magazine, data-vending and software production. Analysts track industry, companies and the economy. Branches in the metros and major cities ensure comprehensive coverage.
The major strength is equity research. Stock-picking for investor’s portfolio is preceded by rigorous research. The advisory services are transmitted through Capital Market magazine, newsletters, Telefolio. Almost 85% of the scrip’s recommended by us show appreciation. On an average we outperform the Bombay Stock Exchange Sensitive Index twice over, and sometime three times. Our independent status insulates us from influence from brokers and other market participants, ensuring that the selection of stocks and research are unbiased.
We are also pioneers in corporate databases - Capitaline, Mutual Fund database - Navindia
For the best experience please go back to portrait mode.